Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (50)

2024

  1. Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 42, Núm. 2, pp. 74-79

  2. Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction

    Antiviral Research, Vol. 231

  3. Integrated transcriptomic landscape of the effect of anti-steatotic treatments in high-fat diet mouse models of non-alcoholic fatty liver disease

    Journal of Pathology, Vol. 262, Núm. 3, pp. 377-389

  4. Interference with mitochondrial function as part of the antifibrogenic effect of Rilpivirine: A step towards novel targets in hepatic stellate cell activation

    Biomedicine and Pharmacotherapy, Vol. 178

  5. Resistance to apoptosis in complicated Crohn's disease: Relevance in ileal fibrosis

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 2

  6. Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD

    Biomedicines, Vol. 12, Núm. 7

  7. The impact of EU public procurement regulations on tenders in Spain: a study with adalimumab

    Frontiers in Pharmacology, Vol. 15

2023

  1. Abacavir causes leukocyte/platelet crosstalk by activating neutrophil P2X7 receptors thus releasing soluble lectin-like oxidized low-density lipoprotein receptor-1

    British Journal of Pharmacology, Vol. 180, Núm. 11, pp. 1516-1532

  2. Anti-inflammatory and immunomodulating effects of rilpivirine: Relevance for the therapeutics of chronic liver disease

    Biomedicine and Pharmacotherapy, Vol. 167

2022

  1. Down-Regulation of the Longevity-Associated Protein SIRT1 in Peripheral Blood Mononuclear Cells of Treated HIV Patients

    Cells, Vol. 11, Núm. 3

  2. Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less

    Cell Death and Disease, Vol. 13, Núm. 4

  3. Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics

    Pharmaceuticals, Vol. 15, Núm. 9

  4. Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz

    Biomedicines, Vol. 10, Núm. 1

  5. SUCNR1 Mediates the Priming Step of the Inflammasome in Intestinal Epithelial Cells: Relevance in Ulcerative Colitis

    Biomedicines, Vol. 10, Núm. 3

2021

  1. Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?

    Frontiers in Pharmacology, Vol. 12

  2. Apoptosis of Hepatocytes: Relevance for HIV-Infected Patients under Treatment

    Cells, Vol. 10, Núm. 2

  3. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved

    Cells, Vol. 10, Núm. 7

  4. Pharmacology and safety of tofacitinib in ulcerative colitis

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 1, pp. 39-48

  5. Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis: are we there yet?

    Journal of Pathology, Vol. 254, Núm. 3, pp. 216-228

2020

  1. p53 and p53-related mediators PAI-1 and IGFBP-3 are downregulated in peripheral blood mononuclear cells of HIV-patients exposed to non-nucleoside reverse transcriptase inhibitors

    Antiviral Research, Vol. 178